Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its fourth quarter earnings conference call on February 10, 2026, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Group 1: Earnings Call Details - The earnings conference call will be accessible via a live audio webcast on Zimmer Biomet's Investor Relations website, with a replay available after the call [2]. - U.S. and Canada participants can join the call by dialing (800) 330-6710, while international callers should use +1 (213) 279-1505, both requiring conference ID 7090861 [2]. Group 2: Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, offering a comprehensive portfolio aimed at enhancing mobility and health [3]. - The company focuses on transforming patient experiences through innovative products and integrated digital and robotic technologies that utilize data analytics and artificial intelligence [3]. - With over 90 years of experience, Zimmer Biomet is committed to delivering high-quality solutions to patients and healthcare providers, reflecting a culture of evolution and innovation [4].

Group 1 - Boston Scientific has agreed to acquire Penumbra, a thrombectomy company, for approximately $15 billion in cash and stock [1] - This acquisition is aimed at strengthening Boston Scientific's cardiovascular portfolio [1]

Group 1 - Boston Scientific announced the acquisition of Penumbra for approximately $14.5 billion [1]

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction i MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement ...

Core Insights - BD has received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, which is set to launch in early 2026, marking a significant advancement in breast health technology [1][2]. Product Overview - The EnCor EnCompass™ Biopsy System is designed to enhance the breast biopsy experience by allowing clinicians to perform procedures across various breast imaging platforms using a single integrated system [2][5]. - Key features include multi-modality use, adjustable vacuum strengths, 360° sampling capability, enhanced visualization tools, and a choice of probe sizes (12G, 10G, and 7G) to accommodate different lesion types [7]. Company Commitment - BD emphasizes its commitment to developing patient-centered solutions that improve early detection and diagnosis of breast diseases, reflecting its ongoing focus on addressing the needs of clinicians and patients [2][3][5]. - The company aims to enhance the safety and efficiency of care delivery while supporting clinical processes through innovative technologies [6].

This article looks at the 14 Best Booming Stocks to Buy Right Now.The S&P 500 registered gains of 16% in 2025, marking the third successive year of double-digit returns after the broad market index rallied 24% in 2023 and then 23% in 2024.Total gains over the past three years have amounted to approximately 80%, the strongest run over a three-year win streak since the index surged 90% between 2019 and 2021.A Financial Times survey of major investment banks in December forecast a 10% gain in the S&P 500 in 20 ...

SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--ASP International GmbH ("ASP†), a division of Fortive (NYSE: FTV), in collaboration with FUJIFILM Healthcare Europe GmbH, proudly announces that the ULTRA GIâ"¢ Cycle has received CE mark approval. The ULTRA GIâ"¢ Cycle is the latest innovation for the STERRADâ"¢ 100NX Sterilizer with ALLClearâ"¢ Technology. The ULTRA GIâ"¢ Cycle's receipt of the CE mark represents a pivotal advancement in elevating patient safety across healthcare facilities and addressing the. ...

Core Viewpoint - DJS Law Group is investigating Beta Bionics, Inc. for potential violations of securities laws following a significant drop in share price due to disappointing patient start forecasts [1][2]. Investigation Details - The investigation centers on whether Beta Bionics made misleading statements or failed to disclose critical information to investors [2]. - On January 8, 2026, Beta Bionics announced an expectation of fewer patient starts in Q4 than analysts had estimated, leading to a 37% decline in share price on January 9, 2026 [2]. DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [3]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Summary of Shenzhen Mindray (300760.SZ) Conference Call Company Overview - Shenzhen Mindray is a leading medical device manufacturer in China, with three core segments: Patient Monitoring and Life Support (PMLS), In Vitro Diagnostics (IVD), and Medical Imaging, contributing 37%, 38%, and 20% of total revenue respectively in FY24 [24][25]. Key Industry Insights - The China medtech sector is supported by government initiatives, an aging population, and increasing healthcare spending, with a recovery in hospital procurement expected in 2026 [3]. - Mindray's overseas business accounts for over 50% of its revenue, with a target to double market share in emerging markets within five years [1][3]. Financial Performance and Projections - **Earnings Summary**: - 2023 Net Profit: Rmb 11,582 million, EPS: Rmb 9.558, P/E: 21.3 [5]. - 2024 Net Profit: Rmb 11,668 million, EPS: Rmb 9.558, P/E: 21.3 [5]. - 2025E Net Profit: Rmb 9,488 million, EPS: Rmb 7.772, P/E: 26.2 [5]. - 2026E Net Profit: Rmb 10,982 million, EPS: Rmb 8.996, P/E: 22.6 [5]. - 2027E Net Profit: Rmb 12,501 million, EPS: Rmb 10.240, P/E: 19.9 [5]. - Expected total return of 42.7% with a target price of Rmb 285, indicating a potential upside of 39.9% from the current price of Rmb 203.680 [6][10]. Strategic Initiatives - **Growth Acceleration**: Management anticipates a return to positive domestic growth in 2026 and further acceleration in 2027, following a temporary margin dip due to strategic investments [1][2]. - **Innovation & High-End Shift**: Focus on high-margin products and a recurring revenue model, particularly in IVD reagents and high-end ultrasound devices [1][2]. - **Digital Ecosystem**: Development of integrated smart hospital solutions combining equipment, IT, and AI to create a competitive advantage [1][19]. Market Position and Valuation - Mindray is viewed as undervalued compared to domestic peers, trading at approximately 23x FY26 P/E versus 38x for peers [2]. - The company aims to increase overseas revenue contributions to 70% of total revenue and become one of the top 20 global medical device companies in the next 5-10 years [25]. Risks and Challenges - Key risks include geopolitical tensions affecting revenue, potential adverse impacts from Group Purchasing Organizations (GPO), patent protection issues, and supply chain disruptions [27]. - The company must navigate challenges in accurately assessing technological trends and customer needs to maintain its competitive position [27]. Conclusion - Mindray is positioned as a top pick in the medtech sector with a strong growth trajectory, strategic international expansion, and a focus on innovation, despite facing certain risks and market challenges [4].

Core Insights - The sixth batch of centralized procurement for high-value medical consumables in China was conducted, involving 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies winning the bid [2][3] Drug-Coated Balloon Market - Drug-coated balloons (DCBs) are now included in the procurement, which helps improve the treatment of vascular stenosis by expanding blood vessels and releasing medication [2] - The market for DCBs has seen significant growth, with usage increasing from 7,500 units in 2016 to 290,000 units in 2021, and is projected to reach 1,000,000 units by 2025 [2] - The market size for DCBs reached 2.01 billion yuan in 2021 and is expected to grow to 5.933 billion yuan by 2030 [2] Competitive Landscape - The DCB market was previously dominated by three companies: Liaoning Yinyi Biological (41.5% market share), Beigang (27.1%), and Lepu Medical (10.4%) in 2021 [3] - The annual demand for coronary DCBs is 614,800 units, indicating a strong market for cardiovascular intervention treatments [3] - Domestic companies are gaining a larger share of the market, with Liaoning Yinyi Biological leading in demand at 113,000 units [3] Procurement Details - The procurement process aims to stabilize clinical use, ensure quality, and prevent price undercutting [5] - The procurement includes a competitive grouping based on demand and supply capabilities, ensuring that high-quality products are selected [5] - Special product functionalities are considered in the procurement process, allowing for differentiated pricing based on clinical value [5] Urological Intervention Consumables - The procurement also included urological intervention consumables, which had previously been a "blank area" in centralized procurement [4] - A total of 454 products from 195 companies bid, with 398 products from 170 companies winning the bid [4] - The inclusion of specialized products like drug-coated balloons and pressure measurement catheters meets specific clinical needs [4]